anti-pro-Atrial Natriuretic Peptide (proANP) (a.a. 40-55) antibody product blog
Tags: Antibody; Monoclonal Antibody; pro-Atrial Natriuretic Peptide (proANP) (a.a. 40-55); anti-pro-Atrial Natriuretic Peptide (proANP) (a.a. 40-55) antibody;
The pro-Atrial Natriuretic Peptide (proANP) (a.a. 40-55) n/a (Catalog #MBS310919) is an Antibody produced from Host: MouseSource: Cell Culture Supernatant and is intended for research purposes only. The product is available for immediate purchase. The MAb to proANP (a.a. 40-55) reacts with Human and may cross-react with other species as described in the data sheet. MyBioSource\'s pro-Atrial Natriuretic Peptide (proANP) (a.a. 40-55) can be used in a range of immunoassay formats including, but not limited to, EIA/ELISA. Researchers should empirically determine the suitability of the pro-Atrial Natriuretic Peptide (proANP) (a.a. 40-55) n/a for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Immunogen: Synthetic human pro-ANP (a.a. 40-55) poly Lysine conjugated ((C)EPNEEAGAALSPLPEV).
Affinity Constant: Not determined. Buffer: Lyophilized from 50mM Tris, HCl, pH 7.4
Preservative: No
Lyophilized: Yes
Important Note: Vial Contains Small Quantity. Centrifuge Product Before Opening!. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing pro-Atrial Natriuretic Peptide (proANP) (a.a. 40-55) are readily searchable from our website. Different antibodies against the same target such as pro-Atrial Natriuretic Peptide (proANP) (a.a. 40-55) may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.